Business Wire

CEL-SCI’s Multikine® Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Vs 48.6%) in the Group Receiving Surgery Plus Radiotherapy in a Landmark Head ...

Data indicate significant overall survival (OS) benefit for patients who received the Multikine® treatment regimen followed by surgery and radiotherapy, but not for patients who had chemotherapy added ...
Ars Technica

Chrome OS is “combining” with Android, but what does that mean?

Android and Chrome OS have been developed in parallel for years, but Google is planning to streamline its operating systems. In a recent interview, Android Ecosystem President Sameer Samat stated ...
Morningstar

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

The overall survival (OS) hazard ratio (HR) in the HARMONi trial was 0.78, with a nominal p-value of 0.0332 In the North American patients, the OS HR was 0.70 The HARMONi trial has already ...
Outside

Head Flexpoint Radical OS ($200)

New perk: Easily find new routes and hidden gems, upcoming running events, and more near you. Your weekly Local Running Newsletter has everything you need to lace up! Subscribe today. Wouldn’t you ...
Yahoo Finance

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

In the HARMONi trial, clinical endpoint benefits, including OS and PFS, were consistent across Western and Asian patient populations, and these results were also in alignment with the clinical data ...